3-氯-2-羟基-6-甲基苯甲醛 | 153782-74-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-氯-2-羟基-6-甲基苯甲醛
• 英文名称: 3-chloro-2-hydroxy-6-methylbenzaldehyde
• CAS: 153782-74-2
• 化学式: C₈H₇ClO₂
• 分子量: 170.595
• InChiKey: LPMXSVMNUSEYPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-氯-2-羟基-6-甲基苯甲醛 在 盐酸 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 26.0h， 生成
  参考文献：
  名称：

  Ugi 反应中的长程非对映选择性：四氢苯并恶氮杂的立体控制和多样性导向合成

  摘要：

  水杨醛和受保护的 1,2-氨基醇已被会聚转化为一系列 2,3-二氢苯并[f][1,4] 氧氮杂卓，它们进行 Ugi-Joullie 多组分反应，具有不寻常的远程非对映选择性。该协议允许非对映选择性制备，只需两个步骤，一系列类似药物的四氢苯并 [f] [1,4] 氧氮杂，并结合引入四个多样性点。还证明了获得对映体纯形式的这些化合物的可能性。

  DOI：

  10.1002/ejoc.201300541
• 作为产物：
  描述：

  2-氯-5-甲酚 在 sodium periodate 、 四氧化锇 、 potassium tert-butylate 、 水 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二甲基亚砜 、 乙腈 、 叔丁醇 为溶剂， 反应 8.0h， 生成 3-氯-2-羟基-6-甲基苯甲醛
  参考文献：
  名称：

  Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes

  摘要：

  In a continuing effort to improve the subtype selectivity and agonist potency of estrogen receptor beta (ER beta) ligands, we have designed and developed a thus far unexplored structural series obtained by molecular refinements of monoaryl-substituted salicylaldoximes (Salaldox B). The most interesting compounds in this series (2c, d) show remarkably high ER beta-binding affinities, with K(i) values reaching the sub-nanomolar range (K(i) = 0.38 nM for 2c and 0.57 nM for 2d), and have very high levels of ER beta-subtype selectivity. Both compounds show a potent full agonist character on ER beta (EC(50) = 0.23 nM for 2c and 1.3 nM for 2d). Furthermore, 2d shows a remarkable functional subtype selectivity, with a beta/alpha transcription potency ratio 50-fold higher than that of estradiol. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.03.030

文献信息

• [EN] CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS<br/>[FR] DERIVES DE CHROMENE A TITRE D'AGENTS ANTI-INFLAMMATOIRES
  申请人：PHARMACIA CORP

  公开号：WO2004087687A1

  公开（公告）日：2004-10-14

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula (I). Wherein Z, X, R1, R2, R3, and R4 are as described in the specification.

  该发明涉及在治疗与环氧合酶-2介导的疾病相关的情况中具有效用的方法和化合物。特别感兴趣的化合物是由式(I)定义的苯并吡喃和它们的类似物。其中Z、X、R1、R2、R3和R4如规范中所述。
• Syntheses of Chromenes and Azachromenes: 2<i>H</i>-1-Benzopyran, 2<i>H</i>-Pyrano[3,2-<i>b</i>]pyridine, 2<i>H</i>-Pyrano[2,3-<i>c</i>]pyridine, and Derivatives
  作者：Dominique Billeret、Dominique Blondeau、Henri Sliwa

  DOI：10.1055/s-1993-25962

  日期：——

  2H-1-Benzopyran and derivatives have been prepared by an intramolecular Wittig reaction in a heterogeneous medium starting from salicylaldehyde, (2-hydroxyalkyl)triphenylphosphonium salts, and potassium carbonate. Extension of this reaction to various o-hydroxyformylpyridines were performed in order to obtain 2H-pyrano[3,2-b]pyridine, 2H-pyrano[2, 3-c]pyridine, and derivatives.

  2H-1-Benzopyran 及其衍生物是由水杨醛、（2-羟基烷基）三苯基鏻盐和碳酸钾在异相介质中通过分子内 Wittig 反应制备的。将该反应扩展到各种邻羟基甲酰基吡啶，从而得到 2H-吡喃并[3,2-b]吡啶、2H-吡喃并[2,3-c]吡啶及其衍生物。
• Benzopyran compounds useful for treating inflammatory conditions
  申请人：Carter Jeffery

  公开号：US20050148777A1

  公开（公告）日：2005-07-07

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R 1 , R 2, R 3 , and R 4 are as described in the specification.

  本发明涉及与环氧合酶-2介导的疾病相关的病症治疗方法和化合物。特别感兴趣的化合物是由公式1定义的苯并吡喃和其类似物，其中Z、X、R1、R2、R3和R4如规范中所述。
• Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
  申请人：Carter Jeffery

  公开号：US20050148627A1

  公开（公告）日：2005-07-07

  The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R 1 , R 2 , R 3 , and R 4 are as described in the specification.

  本发明涉及用于治疗与环氧合酶-2介导的疾病相关的条件的方法和化合物。特别感兴趣的化合物是苯并吡喃和它们的类似物，其由公式1定义，其中Z、X、R1、R2、R3和R4如规范中所述。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。